Drug Profile

BHV 1400

Alternative Names: BHV-1400

Latest Information Update: 10 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biohaven Pharmaceuticals
Class Antibodies
Mechanism of Action Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I IgA nephropathy

Most Recent Events

02 Mar 2026 Biohaven Pharmaceutical plans a phase III pivotal trial for IgA nephropathy in the first quarter of 2026
12 Jan 2026 Efficacy data from a phase I trial in IgA nephropathy released by Biohaven
28 May 2025 Updated efficacy and adverse events data from phase-I trial in IgA nephropathy released by Biohaven Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com